GlobeNewswire by notified

Biotech company Eradivir is developing lead drug EV25 to treat influenza

Share

Company has completed the required preclinical studies and will seek regulatory approval to dose volunteers in Belgium by the end of the year

WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases.

CEO Martin Low said Eradivir’s lead drug EV25 treats influenza, a disease that affects up to 40 million Americans, kills between 10,000 and 50,000, and hospitalizes 150,000 to 750,000 annually.

“EV25 relies on a U.S. Food and Drug Administration-approved drug as a basis to deliver an attached immunogenic payload containing haptens, specifically to the surface of virus and virus-infected cells,” Martin Low (rhymes with “now”) said. “As a result, EV25 both inhibits viral reproduction and kills the flu virus and infected cells.”

Martin Low said EV25 has demonstrated several advantages over current influenza drugs.

“It promotes a quicker recovery even after delaying treatment well beyond the standard 48 hours from the appearance of symptoms,” he said. “It also reduces both the risk of drug resistance and the number of doses required to only one.”

Developmental steps

Eradivir has successfully completed preclinical studies required by regulatory agencies to dose EV25 in humans. 

“A Phase I study, designed to indicate the safety of EV25 in healthy volunteers, is scheduled to begin in Antwerp, Belgium, at the end of the year,” Martin Low said. “Also planned for 2025 are two Phase II studies that will confirm safety and indicate the efficacy of EV25.”

Martin Low said because Eradivir’s overall immunological technology platform has the potential to treat multiple diseases, the company is also conducting studies on other molecules to treat dengue and RSV, or respiratory syncytial virus.

“We have seen some early success and hope to demonstrate proof of concept for one of these molecules by the end of the year,” he said. 

Eradivir leadership

Eradivir’s team has been very successful in developing small molecule therapies in cancer, autoimmune diseases and infectious diseases. Its board members include Philip Low and Raymond Schinazi, who have worked on several drugs that have been approved for the market. 

“We have built a team that understands viruses and how to develop small molecules. Many of us have worked together in the past and know how to get things done,” Martin Low said.

Eradivir’s Purdue University connections

Philip Low is Purdue’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science. He also is on the faculty of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research. He has started seven successful companies based on his research, and three of his drugs have been approved by the FDA.

“It is our goal to continue our discovery work in these areas at Purdue University,” Martin Low said. “Our investors share this vision and have to date contributed over $18 million in financing.”

Philip Low disclosed the immunological technology innovations to the Purdue Innovates Office of Technology Commercialization, which has applied for a patent to protect the intellectual property. OTC licensed the innovations to Eradivir for further development and commercialization. 

About Eradivir

Eradivir’s goal is to focus the power of the immune system to treat disease. Its small-molecule, bispecific immunotherapy tethers a patient’s immune cells specifically to a diseased cell facilitating its rapid and selective destruction. Its first drug to go into humans, EV25, is directed against influenza. 

About Purdue Innovates Office of Technology Commercialization

The Purdue Innovates Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university’s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2023, the office reported 150 deals finalized with 203 technologies signed, 400 disclosures received and 218 issued U.S. patents. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation & Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org for more information.

Writer/Media contact: Steve Martin, sgmartin@prf.org

Source: Martin Low, martin.low@eradivir.com

Attachments

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye